financetom
Business
financetom
/
Business
/
China fines Alibaba record $2.75 billion for anti-monopoly violations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
China fines Alibaba record $2.75 billion for anti-monopoly violations
Apr 10, 2021 2:09 AM

Following a month-long probe, China's market regulator ‘State Administration for Market Regulation’ (SAMR) levied a fine of 18 billion yuan ($2.75 billion) on Jack Ma-owned Alibaba, an e-commerce platform, for alleged violation of anti-monopoly rules and abuse of its dominant market position.

Share Market Live

NSE

Besides the heavy fine — which is around 4 percent of its revenues in 2019 — SAMR has also asked Alibaba will have to file self-examination and compliance reports for the next three years.

In an official statement on Thursday (April 8), SAMR said that Alibaba flouted rules by forcing merchants on its website to sign exclusive cooperation agreements. This, SAMR says, prevents the merchants from selling products on Alibaba's rival platforms.

Shortly after SAMR's punitive action, Alibaba, in a statement posted on its official Weibo account, said that it accepts the penalty and will comply with the norms.

Meanwhile, Beijing authorities also halted new enrolments at an elite business school — Hupan University — backed by Alibaba founder Jack Ma, according to a Financial Times report.

While no clear reason has been stated behind the move, the report suggests that it is a part of the vendetta actions being taken against Jack Ma for his remarks critical of the country’s finance system. In October last year, Ma had slammed the country’s financial regulator saying China's financial system was “the legacy of the Industrial Age” and that Chinese banks are giving loans to companies "that do not need money".

In less than a month after Ma's remark, the Chinese officials had suspended Ant's IPO rollout, which was to be the highest valued public listing ever, in November 2020. Ant, the fintech arm of Alibaba, was expecting to raise $37 billion from the market. Back then, the company had said that the listing was suspended a “significant change” has been made in the regulations related to online lending.

First Published:Apr 10, 2021 11:09 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved